FOLD Amicus Therapeutics Inc Total Asset Value of Company

FOLD (Amicus Pharma) - company brandmark

Amicus Therapeutics dominates the enzyme therapy niche for rare pathologies, solidifying its global status in the US and Europe. On GURU.Markets, total assets by ROA demonstrate financial stability, with the latest reading standing at 866.13. Growth is based on strategic alliances with scientific centers, while commercial success is driven by revolutionary methods for correcting defective proteins to save patients.

FOLD (Amicus Therapeutics) Company Total Assets history from 07/04/2022 to 05/09/2026

Analytical breakdowns and data insights for company Amicus Pharma (FOLD)

- stock quotes and analyst forecast:
Share Price amicusrx.com|FOLD - Price Target Chart
- market capitalization data:
Market Valuation Amicus Corp|FOLD - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Amicus Therapeutics|FOLD - Book Capitalization|Market Capitalization to Book Value Ratio amicusrx.com|FOLD - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Amicus Therapeutics|FOLD - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Amicus Corp|FOLD - Company Aggregate Debts|Debts to Book Capitalization Amicus Corp|FOLD - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Amicus Therapeutics|Quick Liquidity Indicator amicusrx.com
- net income and valuation multiples indicators:
FOLD - Net Profit
Fundamental valuation:Amicus Therapeutics
Manufactured products of Amicus Therapeutics

The full utilization of Amicus Therapeutics (FOLD) biotechnological production capacities for rare disease drugs is directly reflected in the asset trends by ROA. This indicator, calculated inversely through return on assets, combines capital and liabilities, allowing investors to assess the real value of resources and the financial stability of the business amid fierce market competition.

Key competitors

Total Business Assets ASND|Aggregate Company Assets Madrigal Pharmaceuticals, Inc.|Corcept Therapeutics Inc. - Total Asset Value of Company|Company Total Assets RYTM|AKRO (Akero Corp) - Aggregate Asset Value|Company Total Assets MTSR (Metsera Inc)|Company Total Assets moonlaketx.com MLTX|CRNX - Aggregate Company Assets|Aggregate Asset Value NAMS (NewAmsterdam Pharma Company)|Soleno (SLNO) - Aggregate Company Assets|Cumulative Company Assets 89bio Pharma|AGIO (Agios Pharmaceuticals) - Company Total Assets|Company Total Assets structuretx.com|Cumulative Company Assets MDXG (MiMedx)|RZLT (Rezolute Inc) - Aggregate Asset Value|Aggregate Company Assets Lexicon Pharma LXRX|MBX - Cumulative Company Assets|Altimmune, Inc. - Company Total Assets|Company Assets aardvarktherapeutics.com|SGMT (Sagimet Biosciences Inc.) - Cumulative Company Assets|BIOA: Aggregate Business Assets|BMEA (Biomea) - Company Total Assets|Company Total Assets Quince|Company Total Assets GUTS|Aggregate Company Assets VTVT (vtvtherapeutics.com)|Aggregate Company Assets Agape ATP ATPC|Pluristem Therapeutics (PLUR) - Company Assets|SYBX - Aggregate Company Assets|LPCN: Aggregate Company Assets|MTNB: Company Total Assets|SPRB - Company Total Asset Base|Aggregate Company Assets Galecto|Carmell Corp. (CTCX) - Company Total Asset Base|Aggregate Company Assets Lumos Pharma Corp (LUMO)|Cumulative Company Assets Organovo Corp ONVO|Company Total Assets RDUS (Radius Recycling, Inc.)